IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is participating as a platinum sponsor of the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) 2023 Winter Meeting, which is being held in Nashville from March 7-11.
Axonics is sponsoring a symposium on Friday, March 10, titled “Emerging Clinical Evidence for Axonics SNM Therapy.” During the symposium, a panel of physicians will discuss the results of the ARTSTRY registry study, which explores real world outcomes with Axonics sacral neuromodulation (SNM) therapy for patients with overactive bladder, urinary retention and fecal incontinence.
In addition, data highlighting the experience of patients with Axonics SNM therapy will include three poster presentations:
- The Role of Age in the Effectiveness of SNM for OAB – presented by Ayman Mahdy, M.D., Ph.D.
- Effectiveness of the Axonics SNM System in Improving Sleep Quality of Life for Patients Suffering with Nocturia – presented by Michael Kennelly, M.D.
- Efficacy and Durability of the Predictive Programming Algorithm of the Axonics SNM System – presented by Ryan Krlin, M.D.
“The SUFU 2023 Winter Meeting provides an opportunity for physicians to learn more about Axonics SNM therapy and the durable symptom relief patients are experiencing, directly from their peers,” said Karen Noblett, M.D., chief medical officer of Axonics. “We remain focused on the Axonics mission of improving the quality of life for adults with incontinence and as such, clinical efficacy and the patient experience continue to be our north star. We are confident that thoughtful innovation coupled with increased public awareness has the potential to significantly increase the adoption of advanced therapies in the years ahead.”
About Axonics®
Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 1 on the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas and No. 4 on the 2022 Deloitte Technology Fast 500™ following its No. 1 ranking in 2021.
Axonics sacral neuromodulation systems provide adults with overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company’s best-in-class urethral bulking hydrogel, Bulkamid®, provides safe and durable symptom relief to women with stress urinary incontinence. In the U.S., moderate to severe urinary incontinence affects an estimated 28 million women and fecal incontinence affects an estimated 19 million adults. Axonics’ clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit www.axonics.com.
